WO2019159005A3 - Method of treating pain comprising repeated administrations of tetrodotoxin over time - Google Patents
Method of treating pain comprising repeated administrations of tetrodotoxin over time Download PDFInfo
- Publication number
- WO2019159005A3 WO2019159005A3 PCT/IB2019/000164 IB2019000164W WO2019159005A3 WO 2019159005 A3 WO2019159005 A3 WO 2019159005A3 IB 2019000164 W IB2019000164 W IB 2019000164W WO 2019159005 A3 WO2019159005 A3 WO 2019159005A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetrodotoxin
- treating pain
- over time
- repeated administrations
- subsequent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Abstract
Methods of treating pain comprising an initial administration of tetrodotoxin followed by subsequent administrations after a period of time to maintain analgesia. Both the initial administration and subsequent administration of tetrodotoxin may be carried out over multiple days, with dosing taking place multiple times each day. The initial and subsequent administrations may use the same or different routes. Additional pharmaceutically active ingredients may also be included in the subsequent administrations of tetrodotoxin.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862631088P | 2018-02-15 | 2018-02-15 | |
US62/631,088 | 2018-02-15 | ||
US201962802762P | 2019-02-08 | 2019-02-08 | |
US62/802,762 | 2019-02-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2019159005A2 WO2019159005A2 (en) | 2019-08-22 |
WO2019159005A3 true WO2019159005A3 (en) | 2019-09-26 |
Family
ID=67619842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2019/000164 WO2019159005A2 (en) | 2018-02-15 | 2019-02-15 | Tetrodotoxin multidose methods of treatment |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019159005A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006097358A2 (en) * | 2005-03-18 | 2006-09-21 | Wex Pharmaceuticals, Inc. | Analgesic combination of sodium channel blockers with opioid antagonists |
WO2007025212A2 (en) * | 2005-08-25 | 2007-03-01 | Wex Pharmaceuticals, Inc. | Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment |
WO2007025213A2 (en) * | 2005-08-25 | 2007-03-01 | Wex Pharmaceuticals, Inc. | Use of sodium channel blockers for the management of musculoskeletal pain |
-
2019
- 2019-02-15 WO PCT/IB2019/000164 patent/WO2019159005A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006097358A2 (en) * | 2005-03-18 | 2006-09-21 | Wex Pharmaceuticals, Inc. | Analgesic combination of sodium channel blockers with opioid antagonists |
WO2007025212A2 (en) * | 2005-08-25 | 2007-03-01 | Wex Pharmaceuticals, Inc. | Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment |
WO2007025213A2 (en) * | 2005-08-25 | 2007-03-01 | Wex Pharmaceuticals, Inc. | Use of sodium channel blockers for the management of musculoskeletal pain |
Non-Patent Citations (2)
Title |
---|
HAGEN ET AL., CURRENT ONCOLOGY, vol. 18, no. 3, 2011, pages e110 - e116 * |
HAGEN ET AL.: "Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial", PAIN RESEARCH AND MANAGEMENT, vol. 2017, 7212713, 7 May 2017 (2017-05-07), XP055636697 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019159005A2 (en) | 2019-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
MX2020007625A (en) | Mtor inhibitor, pharmaceutical composition and use thereof. | |
CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
PH12018550062A1 (en) | Topical film-forming spray | |
CA3010829A1 (en) | Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof | |
WO2007112453A3 (en) | Methods amd compositions for treating conditions | |
PH12017502376A1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
MX2022006533A (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof. | |
MX2020002889A (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof. | |
MX2023000187A (en) | Dosing of vibegron for treatment of overactive bladder. | |
WO2017091767A3 (en) | Drug formulations for cancer treatment | |
MX2016016400A (en) | Stabilized oxymetazoline formulations and their uses. | |
WO2019159005A3 (en) | Method of treating pain comprising repeated administrations of tetrodotoxin over time | |
MX2022003945A (en) | Method for treating hiv with cabotegravir and rilpivirine. | |
MX2020010747A (en) | Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment. | |
EP3741759A4 (en) | Heterocyclic compound, preparation method and use thereof in medicine | |
WO2020243273A3 (en) | Methods of treating cholangiocarcinoma | |
WO2019126695A3 (en) | Methods and pharmaceutical compositions for treating candida auris in blood | |
MX2021003668A (en) | Ketamine composition for use in a method of treatment of depression by pulmonary administration. | |
MX2021002459A (en) | Abuse deterrent immediate release capsule dosage forms. | |
薛茹霞 | In the Peach Garden | |
EP3737763A4 (en) | Pharmaceutical composition for preventing or treating muscular disease or cachexia comprising, as active ingredient, mirna located in dlk1 -dio3 cluster or variant thereof | |
Xuehe | President Li Xiaolin meets with Kentucky Governor Matthew Bevin | |
Kešetović | VLADIMIR N. CVETKOVIĆ, SOCIOLOGY OF POLITICS | |
Mingle | The Influence of Corporate Governance Practices of Banks on Employee Loyalty in Ghana |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19753741 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19753741 Country of ref document: EP Kind code of ref document: A2 |